You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

Article metrics

Article menu
Emerging technologies, pharmacology and therapeutics
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline

 

Online download statistics by month:

Online download statistics by month: January 2022 to September 2024

AbstractFullPdf
Jan 2022460464103
Feb 202243342475
Mar 202220119339
Apr 202219219252
May 202215815944
Jun 202214814737
Jul 202215015128
Aug 202214014240
Sep 202212712860
Oct 202214314344
Nov 202212512425
Dec 202221621433
Jan 202311811539
Feb 202311812655
Mar 202310710230
Apr 20231029936
May 202311411538
Jul 202311811645
Aug 202311311830
Sep 202314414063
Oct 202313413729
Nov 202314114326
Dec 202316716467
Jan 2024625326
Feb 2024807928
Mar 202412912660
Apr 202411411251
May 202411510939
Jun 202411911554
Jul 202414813831
Aug 2024968143
Sep 202410910430
Total484147731400